Momelotinib for the treatment of myelofibrosis

2.

Asshoff

M

,

Petzer

V

,

Warr

MR

, et al.

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

.

Blood

.

2017

;

129

(

13

):

1823

-

1830

.

3.

Chifotides

HT

,

Bose

P

,

Verstovsek

S

.

Momelotinib: an emerging treatment for myelofibrosis patients with anemia

.

J Hematol Oncol

.

2022

;

15

(

1

):

7

.

4.

Oh

ST

,

Talpaz

M

,

Gerds

AT

, et al.

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

.

Blood Adv

.

2020

;

4

(

18

):

4282

-

4291

.

5.

Pardanani

A

,

Gotlib

J

,

Roberts

AW

, et al.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

.

Leukemia

.

2018

;

32

(

4

):

1035

-

1038

.

6.

Tefferi

A

,

Barosi

G

,

Mesa

R

, et al.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)

.

Blood

.

2006

;

108

(

5

):

1497

-

1503

.

7.

Pardanani

A

,

Laborde

RR

,

Lasho

TL

, et al.

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor in myelofibrosis

.

Leukemia

.

2013

;

27

(

6

):

1322

-

1327

.

8.

Mesa

R

,

Verstovsek

S

,

Platzbecker

U

, et al.

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

.

Haematologica

.

2024

;

109

(

2

):

676

-

681

.

9.

Gangat

N

,

Begna

KH

,

Al-Kali

A

, et al.

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

.

Am J Hematol

.

2023

;

98

(

2

):

282

-

289

.

10.

Pardanani

A

,

Abdelrahman

RA

,

Finke

C

, et al.

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

.

Leukemia

.

2015

;

29

(

3

):

741

-

744

.

11.

Abdelrahman

RA

,

Begna

KH

,

Al-Kali

A

, et al.

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

.

Br J Haematol

.

2015

;

169

(

1

):

77

-

80

.

12.

Tefferi

A

,

Barraco

D

,

Lasho

TL

, et al.

Momelotinib therapy for myelofibrosis: a 7-year follow-up

.

Blood Cancer J

.

2018

;

8

(

3

):

29

.

13.

Mesa

R

,

Harrison

C

,

Oh

ST

, et al.

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

.

Leukemia

.

2022

;

36

(

9

):

2261

-

2268

.

14.

Mesa

RA

,

Kiladjian

JJ

,

Catalano

JV

, et al.

SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis

.

J Clin Oncol

.

2017

;

35

(

34

):

3844

-

3850

.

15.

Harrison

CN

,

Vannucchi

AM

,

Platzbecker

U

, et al.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

.

Lancet Haematol

.

2018

;

5

(

2

):

e73

-

e81

.

16.

Gerds

AT

,

Verstovsek

S

,

Vannucchi

AM

, et al.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

.

Lancet Haematol

.

2023

;

10

(

9

):

e735

-

e746

.

17.

Mesa

R

,

Oh

ST

,

Gerds

AT

, et al.

Momelotinib reduces transfusion requirements in patients with myelofibrosis

.

Leuk Lymphoma

.

2022

;

63

(

7

):

1718

-

1722

.

18.

Verstovsek

S

,

Kantarjian

HM

,

Estrov

Z

, et al.

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

.

Blood

.

2012

;

120

(

6

):

1202

-

1209

.

19.

Vannucchi

AM

,

Kantarjian

HM

,

Kiladjian

J-J

, et al.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

.

Haematologica

.

2015

;

100

(

9

):

1139

-

1145

.

20.

Mesa

RA

,

Hudgens

S

,

Floden

L

, et al.

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies

.

Cancer Med

.

2023

;

12

(

9

):

10612

-

10624

.

21.

Hudgens

S

,

Verstovsek

S

,

Floden

L

, et al.

Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies

.

Value Health

.

2024

;

27

(

5

):

607

-

613

.

22.

Oh

ST

,

Verstovsek

S

,

Gupta

V

, et al.

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

.

EJHaem

.

2024

;

5

(

1

):

105

-

116

.

23.

Vachhani

P

,

Verstovsek

S

,

Bose

P

.

Disease modification in myelofibrosis: an elusive goal?

.

J Clin Oncol

.

2022

;

40

(

11

):

1147

-

1154

.

24.

Verstovsek

S

,

Gerds

AT

,

Vannucchi

AM

, et al.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

.

Lancet

.

2023

;

401

(

10373

):

269

-

280

.

25.

Verstovsek

S

,

Mesa

R

,

Gupta

V

, et al.

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

.

Blood Adv

.

2023

;

7

(

14

):

3582

-

3591

.

26.

Chifotides

HT

,

Verstovsek

S

,

Bose

P

.

Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments

.

Cancers (Basel)

.

2023

;

15

(

13

):

3331

.

27.

Oh

ST

,

Mesa

RA

,

Harrison

CN

, et al.

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

.

Blood Adv

.

2023

;

7

(

19

):

5835

-

5842

.

28.

Klenche

BJ

,

Donahue

R

,

Gorsh

B

,

Ellis

C

,

Kawashima

J

,

Strouse

B

.

Anemia-related response end points in myelofibrosis clinical trials: current trends and needs for renewed consensus

.

Future Oncol

.

2024

;

20

(

11

):

703

-

715

.

29.

Hernández-Boluda

J-C

,

Correa

J-G

,

Alvarez-Larrán

A

, et al.

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

.

Br J Haematol

.

2018

;

181

(

3

):

397

-

400

.

30.

Kiladjian

JJ

,

Vannucchi

AM

,

Gerds

AT

, et al.

Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials

.

Hemasphere

.

2023

;

7

(

11

):

e963

.

31.

Rampal

RK

,

Grosicki

S

,

Chraniuk

D

, et al.

Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind phase 3 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

628

.

https://doi.org/10.1182/bloodadvances.2024012939.

32.

Gerds

AT

,

Harrison

CN

,

Kiladjian

J-J

, et al.

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

.

Blood Adv

.

Published online 31 May 2024

33.

Rein

LAM

,

Chaer

FE

,

Yuda

J

, et al.

Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

626

.